The influence of oral contraception on the 1 mg overnight dexamethasone suppression test

Completed

• Conditions: Cushing's syndrome; hypercorticism; 10001353

• Registration Number: NL-OMON36254
• Lead Sponsor: Slingeland Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

use of oral contraception

Exclusion Criteria

Cushing's syndrome, psychiatric diseases, alcohol use of more than 7 units/week, pregnancy, steroid medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Serum cortisol after the 1 mg overnight dexamethasone suppression test during<br /><br>use of OAC and after one and six weeks of ceasing of contraception.<br /><br>Urinary and salivary cortisol during use of OAC and after one and six weeks of<br /><br>ceasing of contraception.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>If necessary: CBG, ACTH, free cortisol, FSH, LH</p><br>